MiR-26a inhibits prostate cancer progression by repression of Wnt5a

Zhao, Shijia; Ye, Xiangdong; Xiao, Lei; Lian, Xuexiong; Feng, Yupeng; Li, Feng; Li, Li

doi:10.1007/s13277-014-2206-4

Cited by 53 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although miR-26a and HMGA1 were selected from statistical analysis, further analyses confirmed that these molecules affected the migration, invasion and growth properties of a human adenocarcinoma cell line. These results were consistent with previous studies, in which miR-26a was identified as a tumor suppressor (14,15) and HMGA1 as an oncoprotein (16) in various cell types. Accordingly, a combined approach, which evaluates cell lines using miRNA-seq may assist in identifying miRNAs, which are biologically relevant in particular cancer cell types.…”

Section: Discussionsupporting

confidence: 94%

Expression of miR-26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells

Sekimoto

Suzuki

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

Lung cancer is the most common cause of cancer-associated mortality worldwide, and the number of cases is increasing annually. Several studies have shown that microRNAs (miRNAs) control proliferation, differentiation, and apoptosis in various cell types, and increasing evidence indicates the presence of aberrant miRNA expression profiles and unique miRNA signaling pathways in several types of cancer. The present study aimed to identify miRNAs, which correlated specifically with the progression of lung cancer through the analysis of 57,100 transcripts and 1,341 small RNA expression profiles in 26 lung adenocarcinoma cell lines using next-generation sequencing. The most marked negative correlation was found between the expression of hsa-miR-26a-1 and messenger RNA (mRNA), and a list of mRNAs, which exhibited negative correlation with hsa-miR-26a-1 were investigated. The most marked negative correlation was observed between the expression levels of hsa-miR-26a-1 and high mobility group A1 (HMGA1). Using a lung adenocarcinoma cell line, the present study analyzed the effect of the overexpression of miR-26a on the expression of HMGA1 and found that miR-26a repressed the expression of HMGA1 by reducing the mRNA levels of HMGA1. Furthermore, it was demonstrated that the overexpression of miR-26a in a lung adenocarcinoma cell line repressed cell migration, invasion and growth by targeting HMGA1. Taken together, the present study showed a significant negative correlation between the expression of miR-26a and HMGA1 in 26 lung adenocarcinoma cell lines, and provided evidence that the suppression of miR-26a supports the progression of cancer by stimulating the expression of HMGA1.

show abstract

Section: Discussionsupporting

confidence: 94%

Expression of miR-26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells

Sekimoto

Suzuki

et al. 2016

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…The tumor-suppressive properties of miR-26 family have been widely reported for many cancers, such action being exerted via targeting of several oncogenes. For miR-26a, targeting of HMGA1 has been documented for bladder cancer,42 and targeting of HMGA2 for gallbladder cancer,43 targeting of FGF9 for gastric cancer,44 targeting of CKS2 for papillary thyroid carcinoma,45 targeting of NRAS and E2F2 for gastric cancer,46 and targeting of Wnt5a for PCa have been documented,47 while for miR-26b, targeting of COX-2 for lung cancer,48 EphA2 for glioma,49 USP9X for hepatocellular carcinoma,50 MIEN1 for non-small-cell lung cancer,51 and ULK2 for PCa52 have been documented. In PCa, both miR-26a and miR-26b target La-related protein 1 53.…”

Section: Discussionmentioning

confidence: 99%

Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

Cochetti¹,

Poli²,

Guelfi³

et al. 2016

OTT

View full text Add to dashboard Cite

IntroductionDiagnosis of prostate cancer (PCa) is based on prostate biopsy that is performed when prostate specific antigen (PSA) is persistently altered over time and/or abnormal digital rectal examination is found. Serum PSA levels increase in both PCa and benign prostatic hyperplasia, leading to an increased number of unnecessary biopsies. There is an urgent need to unravel PCa-specific molecular signatures.Patients and methodsThis study aimed at characterizing a panel of circulating micro RNAs (miRNAs) that could distinguish PCa from benign prostatic hyperplasia in a population of age-matched patients with increased PSA levels. Both miRNAs targeting genes involved in PCa onset and miRNAs whose role in PCa has been highlighted in other studies were included. For this purpose, let-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-24-3p, miR-23b-3p, miR-27-b-3p, miR-106a-5p, miR-20b-5p, miR-18b-5p, miR-19b-2-5p, miR-363-3p, miR-497, miR-195, miR-25-3p, miR-30c-5p, miR-622, miR-874-3p, miR-346 and miR-940 were assayed through real-time PCR in 64 patients with PCa and compared with 60 patients with benign prostatic hyperplasia. The ability of miRNAs to predict the stage of disease was also analyzed.ResultsLet-7c, let-7e, let-7i, miR-26a-5p, miR-26b-5p, miR-18b-5p and miR-25-3p were able to discriminate patients with PCa from those harboring benign prostatic hyperplasia, both presenting altered PSA levels (>3 ng/mL). MiR-25-3p and miR-18b-5p showed the highest sensitivity and specificity to predict PCa, respectively. The combination of these two miRNAs improved the overall sensitivity. A correlation between pathological Gleason score and miRNA expression levels was reported; miR-363-3p, miR-26a-5p, miR-26b-5p, miR-106a-5p, miR-18b-5p, miR-25-3p and let-7i decreased in expression concomitantly with an increase in malignancy.ConclusionThis study confirms serum miRNAs to be reliable candidates for the development of minimally invasive biomarkers for the diagnosis and prognosis of PCa, particularly in those cases where PSA acts as a flawed marker.

show abstract

“…Mature miRNAs can specifically bind to the 3'-untranslated regions (3'-UTRs) of target cellular mRNA, in turn triggering mRNA degradation or inhibition of translation (9). A previous study has reported that miRNA-26a (miR-26a) had decreased expression in prostate cancer (10). However, there is limited knowledge about the role of miR-26a in prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2

2016

View full text Add to dashboard Cite

Abstract. ) is expressed at lower levels in prostate cancer cells compared with normal prostate cells. However, the regulatory mechanism of miR-26a in tumorigenesis and metastasis is not clear. In the present study, the expression profile of cellular miR-26a was analyzed by reverse transcription-quantitative polymerase chain reaction. The potential target of miR-26a was identified by luciferase assay and western blotting. Examination of miR-26a function was performed by transfection with miR-26a mimics and inhibitor. It was found that miR-26a expression was decreased in prostate cancer tissues and cell lines, with androgen-independent prostate cancer (AIPC) showing lower miR-26a expression compared with androgen-dependent prostate cancer (ADPC). Overexpression of miR-26a by transfecting miR-26a mimics could significantly enhance apoptosis, and this upregulation of apoptosis was triggered by cytochrome c oxidase subunit II inhibition. Furthermore, it was found that lower miR-26a density resulted in an evidently poor prognosis. Understanding the important roles of miR-26a in regulating cell apoptosis in human prostate cancer cells may aid the exploration of AIPC transformation mechanisms and contribute to the development of miRNA-based therapy in the future.

show abstract

MiR-26a inhibits prostate cancer progression by repression of Wnt5a

Cited by 53 publications

References 25 publications

Expression of miR-26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells

Expression of miR-26a exhibits a negative correlation with HMGA1 and regulates cancer progression by targeting HMGA1 in lung adenocarcinoma cells

Different levels of serum microRNAs in prostate cancer and benign prostatic hyperplasia: evaluation of potential diagnostic and prognostic role

Downregulated microRNA-26a modulates prostate cancer cell proliferation and apoptosis by targeting COX-2

Contact Info

Product

Resources

About